Upcoming Earnings Schedules, Conferences and Quarterly Financial Results - Research Report on Supernus, Ironwood, Neurocrine Biosciences, PhotoMedex, and Kythera
NEW YORK, November 11, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), Neurocrine Biosciences, Inc. (NASDAQ: NBIX), PhotoMedex, Inc. (NASDAQ: PHMD), and Kythera Biopharmaceuticals, Inc. (NASDAQ: KYTH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Supernus Pharmaceuticals, Inc. Research Report
On November 6, 2013, Supernus Pharmaceuticals, Inc. (Supernus) announced that it expects to report its Q3 2013 financial results on November 12, 2013, after the market closes. On the same day, the Company will host a conference call at 5:00 p.m. ET / 2:00 p.m. PT to review the results, as well as to provide a business update. The Full Research Report on Supernus Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Ironwood Pharmaceuticals, Inc. Research Report
On November 6, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) announced that it will present a corporate update at the Credit Suisse 2013 Healthcare Conference. The Company will be presenting on November 12, 2013 at 3:30 p.m. MT / 5:30 p.m. ET. A live webcast of Ironwood's presentation will be accessible through the Investors section of the Company's website. The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Neurocrine Biosciences, Inc. Research Report
On October 29, 2013, Neurocrine Biosciences, Inc. (Neurocrine Biosciences) reported its Q3 2013 financial results. During the quarter, the Company's revenues totaled $0.7 million, down 92.2% YoY. According to the Company, the entire reduction in revenue was due to the successful completion of the sponsored research and development phases of the Company's license agreements with AbbVie and Boehringer Ingelheim during 2012. Q3 2013 net loss was $11.1 million, or $0.17 loss per share, compared with net loss of $3.1 million, or $0.05 loss per share, in Q3 2012. For full-year 2013, Neurocrine Biosciences expects net loss in the range of $46 million to $47 million, or approximately $0.70 loss per share (based on 67 million basic common shares outstanding at year end). The Full Research Report on Neurocrine Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PhotoMedex, Inc. Research Report
On November 6, 2013, PhotoMedex, Inc. (PhotoMedex) reported its Q3 2013 financial results. In Q3 2013, the Company reported revenues of $45.9 million, down 19.0% YoY primarily due to no consumer sales to the Company's distributor in Japan during the quarter. For Q4 2013, PhotoMedex expects revenues to be more than $55 million, without any expected revenue contribution from Japan. Q3 2013 net income was $0.9 million, or $0.04 per diluted share, compared with $7.5 million, or $0.35 per diluted share, in Q3 2012. Commenting on the results, Dr. Dolev Rafaeli, CEO of PhotoMedex said, "While a change in business model at our distributor in Japan impacted orders for the no!no! during the quarter, we are pleased that product demand from Japanese consumers held steady. In addition, a major beauty event on HSN that occurred in last year's third quarter will take place this year in the fourth quarter. At this event last year, we sold a record number of no!no! products and we are looking forward to a similarly strong reception in December when we will offer the no!no! Pro, which has a higher average selling price." The Full Research Report on PhotoMedex, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Kythera Biopharmaceuticals, Inc. Research Report
On November 1, 2013, Kythera Biopharmaceuticals, Inc. (Kythera) announced that it will release its Q3 2013 operating results on November 14, 2013. On the same day, the Company will host an investor call and webcast at 1:30 p.m. PST to discuss the results. The Full Research Report on Kythera Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to making mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner